Changes in cytokine profile during local IL-2 therapy in cancer patients

被引:0
|
作者
Tomova, R
Pomakov, J
Jacobs, JJL
Adjarov, D
Popova, S
Altankova, I
Den Otter, W
Krastev, Z
机构
[1] Univ Hosp St Ivan Rilski, Gastrointestinal Clin, Sofia 1431, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Clin Immunol, Sofia 1431, Bulgaria
[3] Univ Hosp St Ivan Rilski, Dept Clin Lab, Sofia 1431, Bulgaria
[4] Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3508 TD Utrecht, Netherlands
关键词
IL-2; therapy; cytokines; IL-5; IL-10;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Exogenous interleukin 2 (IL-2) can influence the complex cytokine network in vivo. This study investigated the cytokine profile of patients with different malignancies before and after local IL-2 administration. Patients and Methods: The human TH1 / TH2 cytometric bead array (CBA) kit was used to investigate IL-2, IFN gamma, TNF alpha. IL-4, IL-5 and IL- 10 in a control group and in 13 patients. Results: The baseline serum IL-4 levels in patients were lower than in healthy controls, while the baseline ascitic IL-10 levels in patients was higher than in serum. The IL-2 applications induced a strong serum increase in IL-2 and IL-5 and even more in ascites, while IL-10 increased weakly and mainly locally. One month after the start of therapy, the serum IFN gamma had increased in patients, reaching the level of the control group. Conclusion: After local injection, IL-2 probably leaks into the blood circulation. The higher increases of IL-2, IL-5 and IL-10 in ascites compared to the serum suggests that the injected cytokines and their effects are mainly local. The minor increase of the immunosuppressive IL-10 could explain the therapeutic difference between local and systemic IL-2 therapy since IL-10 levels markedly increase after systemic IL-2 therapy. IL-5 was always increased after IL-2 therapy and, consequently, may be a downstream mediator of antitumour responses.
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [21] Electroporation delivery of IL-2 plasmid for therapy of cancer
    Horton, Holly M.
    Planchon, Rod
    Rolland, Alain
    Kaslow, David
    CANCER RESEARCH, 2006, 66 (08)
  • [22] IMMUNOENDOCRINE THERAPY WITH INTERLEUKIN-2 (IL-2) AND MEDROXYPROGESTERONE ACETATE (MPA) - A RANDOMIZED STUDY WITH OR WITHOUT MPA IN METASTATIC RENAL-CANCER PATIENTS DURING IL-2 MAINTENANCE TREATMENT AFTER RESPONSE OR STABLE DISEASE TO IL-2 SUBCUTANEOUS THERAPY
    LISSONI, P
    BARNI, S
    TANCINI, G
    BRIVIO, F
    CARDELLINI, P
    VAGHI, M
    FOSSATI, V
    FRIGERIO, F
    TUMORI, 1993, 79 (04) : 246 - 249
  • [23] LOCAL IL-2 IN LOCALLY ADVANCED BREAST-CANCER
    DALGLEISH, AG
    SAUVEN, P
    FERMONT, D
    MCINTYRE, B
    BURKE, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1990, 9 (04) : 237 - 238
  • [24] ROLE OF INTERLEUKIN-2 (IL-2) IN CANCER-RELATED IMMUNE-DEFICIENCY - INVITRO RESPONSE TO IL-2, PRODUCTION OF IL-2, AND IL-2 RECEPTOR EXPRESSION IN PATIENTS WITH ADVANCED CANCER
    MANTOVANI, G
    COIANA, A
    MASSIDDA, A
    PROTO, E
    FLORIS, C
    MACCIO, A
    PUSCEDDU, G
    DELGIACCO, GS
    CANCER DETECTION AND PREVENTION, 1988, 12 (1-6): : 149 - 159
  • [26] Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2: Preliminary considerations
    Lissoni, P
    Fumagalli, L
    Di Felice, G
    Mengo, S
    Mauri, E
    Merlini, D
    Meregalli, S
    Rovelli, F
    Barni, S
    Tancini, G
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1997, 13 (1-2): : 17 - 23
  • [27] Effective IL-2 therapy
    DenOtter, W
    Everse, LA
    Bernsen, MR
    Klein, WR
    Rutten, VPGM
    Stewart, R
    Hill, G
    Balemans, L
    Steerenberg, PA
    FiszerMaliszewska, L
    Dobrowolski, Z
    Zembala, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 24 - 24
  • [28] IL-2 GENE-THERAPY OF CANCER - AT ITS BEGINNING
    BUBENIK, J
    FOLIA BIOLOGICA, 1993, 39 (06) : 279 - 288
  • [29] Peripheral T lymphocyte cytokine profile (IFNγ, IL-2, IL-4) and CD30 expression/release during measles infection
    Vinante, F
    Krampera, M
    Morosato, L
    Rigo, A
    Romagnani, S
    Pizzolo, G
    HAEMATOLOGICA, 1999, 84 (08) : 683 - 689
  • [30] A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
    Alfredo Quijano-Rubio
    Aladdin M. Bhuiyan
    Huilin Yang
    Isabel Leung
    Elisa Bello
    Lestat R. Ali
    Kevin Zhangxu
    Jilliane Perkins
    Jung-Ho Chun
    Wentao Wang
    Marc J. Lajoie
    Rashmi Ravichandran
    Yun-Huai Kuo
    Stephanie K. Dougan
    Stanley R. Riddell
    Jamie B. Spangler
    Michael Dougan
    Daniel-Adriano Silva
    David Baker
    Nature Biotechnology, 2023, 41 : 532 - 540